Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations

Current Oncology

Volumn 22, Issue 1, 2015, Pages 49-59

  Carrier, Marc ^a   Lazo Langner A ^b   Shivakumar, S ^c   Tagalakis, V ^d   Gross, P L ^e   Blais, N ^f   Butts, C A ^g   Crowther, M ^h  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Deep vein thrombosis; Pulmonary embolism; Recommendations; Venous thromboembolism

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; D DIMER; DABIGATRAN; DALTEPARIN; EDOXABAN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ALGORITHM; ARTICLE; BIOACCUMULATION; CANCER INFILTRATION; CATHETER THROMBOSIS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FUNDING; HUMAN; KIDNEY FAILURE; LUNG ANGIOGRAPHY; META ANALYSIS (TOPIC); NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84922911740     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2392     Document Type: Article

References (41)

1. Horsted F, West J, Grainge MJ. Risk of venous thrombo-embolism in patients with cancer: a systematic review and meta-analysis. PLoS Med2012;9:e1001275.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous throm-boembolism among hospitalized cancer patients. Cancer2007;110:2339–46.
3. Lyman GH, Khorana AA, Kuderer NM, et al. on behalf of American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189–204.
4. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease. Ver. 2.2011. Fort Washington, PA: nccn; 2012. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf (free registration required); cited January 10, 2012]
5. Kearon C, Akl EA, Comerota AJ, et al. on behalf of the American College of Chest Physicians. Antithrombotic therapy for vte disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl):e419S–94S.
6. Guyatt GH, Oxman AD, Kunz R, et al. on behalf of the grade Working Group. grade: going from evidence to recommendations. BMJ 2008;336:1049–51.
7. van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman M V, Klok FA. Meta-analysis of the effcacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014;12:1116–20.
8. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest 2014;:[Epub ahead of print].
9. Carrier M, Cameron C, Delluc A, Castellucci L, Khorana A, Lee AYY. Efficacy and safety of a nticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res2014;134:1214–19.
10. Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014;123:3972–8.
11. Kakkar A, Kessler C, Goldhaber SZ, et al. Dalteparin sodium for the long-term management of venous thrombembolism in cancer patients. The daltecan study [abstract]. J Thromb Haemost 2013;11(suppl 2):18–19.
12. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011;29:2405–9.
13. Dentali F, Ageno W, Pierfranceschi MG, et al. Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost2011;9:1081–3.
14. Franklin JM, Rahman N, Gleeson FV. The clinician’s response to a report of an incidental pulmonary embolism detected on multidetector ct. Postgrad Med J2011;87:746–9.
15. O’Connell CL, Boswell WD, Duddalwar V, et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol2006;24:4928–32.
16. Abdel-Razeq HN, Mansour AH, Ismael YM. Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome—a comprehensive cancer center experience. Vasc Health Risk Manag2011;7:153–8.
17. Sun JM, Kim TS, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer2010;69:330–6.
18. Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Buller HR. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res2010;125:e306–9.
19. Gollin G, Ward B, Meier GH, Sumpio BE, Gusberg RJ. Central splanchnic venous thrombosis. Often unsuspected, usually uncomplicated. J Clin Gastroenterol1994;18:109–13.
20. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost2009;7:760–5.
21. Kleinjan A, Di Nisio M, Beyer–Westendorf J, et al. Safety and feasibility of a diagnostic algorithm combining clinical probability, D-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. Ann Intern Med 2014;160:451–7.
22. Di Nisio M, Van Sluis GL, Bossuyt PM, Büller HR, Porreca E, Rutjes AW. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost2010;8:684–92.
23. Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost2007;5:1650–3.
24. Lee AY, Levine MN, Baker RI, et al. on behalf of the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (clot) investigators. Low-molecular-weight heparin versus a coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.
25. Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res2009;123:837–44.
26. Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res2014;134:93–5.
27. Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001;111:270–3.
28. Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY on behalf of the Subcommittee on Haemostasis and Malignancy for the Scientifc and Standardization Committee (ssc) of the International Society on Thrombosis and Haemostasis (isth). Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the ssc of the isth. J Thromb Haemost 2013;11:1760–5.
29. Dush AD, Ray L, Li Q, Yucebay F, Kraut EH. Management of recurrent venous thromboembolism in patients with cancer. Presented at: The 12th National Conference on Anticoagulant Therapy; Phoenix, AZ, U.S.A.; May 9–11, 2013. [Available online at: http://www.acforum2013.org/ac_public/core_routines/view_abstract_no.php?show_close_window=yes&abstractno=10; cited November 27, 2014]
30. Ray L, Dush A, Li Q, Yucebay F, Kraut E. Management of recurrent venous thromboembolism in patients with cancer [abstract]. J Oncol Pharm Pract 2013;19:.
31. Saccullo G, Marietta M, Carpenedo M, et al. Platelet cut-off for anticoagulant therapy in cancer patients with venous thrombo-embolism and thrombocytopenia: an expert opinion based on rand/ucla appropriateness method (ram) [abstract 581]. Blood 2013;122:. [Available online at: https://ash.confex.com/ash/2013/webprogram/Paper61771.html;cited November 27, 2014]
32. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thrombo-embolism (vte) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for vte prevention. Blood2008;112:504–1 0.
33. Whitney BA, Kerstein MD. Thrombocytopenia and cancer: use of the Kim–Ray Greenfeld filter to prevent thromboem-bolism. South Med J1987;80:1246–8.
34. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost2009;7:1629–32.
35. Cook DJ, Meade M, Guyatt G, et al. on behalf of the protect Investigators for the Canadian Critical Care Trials Group and the Australian a nd New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364:1305–14.
36. Cook DJ, Douketis J, Meade M, et al. on behalf of the Canadian Critical Care Trials Group. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008;12:R32.
37. Douketis JD, Cook D, Meade M, et al. on behalf of the Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the direct study. Arch Intern Med 2008;168:1805–12.
38. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost2007;97:581–6.
39. Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol2012;68:757–65.
40. Rodger MA, Ramsay T, MacKinnon M, et al. Tinzaparin versus dalteparin for periprocedure prophylaxis of thrombo-embolic events in hemodialysis patients: a randomized trial. Am J Kidney Dis2012;60:427–34.
41. Levine M N, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti–factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost1989;62:940–4.